Target Price | $10.67 |
Price | $0.87 |
Potential |
1,127.89%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Moleculin Biotech, Inc. 2026 .
The average Moleculin Biotech, Inc. target price is $10.67.
This is
1,127.89%
register free of charge
$20.00
2,202.29%
register free of charge
$4.00
360.46%
register free of charge
|
|
A rating was issued by 3 analysts: 3 Analysts recommend Moleculin Biotech, Inc. to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Moleculin Biotech, Inc. stock has an average upside potential 2026 of
1,127.89%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -6.32 | -1.36 |
58.06% | 78.48% | |
P/E | negative |
1 Analysts have issued a Moleculin Biotech, Inc. forecast for earnings per share. The average Moleculin Biotech, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Moleculin Biotech, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
Maxim Group |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 24 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
Maxim Group |
Locked
➜
Locked
|
Locked | Nov 12 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 25 2025 |
Locked
Maxim Group:
Locked
➜
Locked
|
Mar 25 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 24 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
Maxim Group:
Locked
➜
Locked
|
Nov 12 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.